Proactiveinvestors Australia - Pharma & Biotech RSS feed Proactiveinvestors Australia - Pharma & Biotech feed en Sun, 21 Jan 2018 17:07:44 +1100 Genera CMS PolyNovo to jointly develop medical devices for use in breast surgery Thu, 18 Jan 2018 14:38:00 +1100 Bod Australia taps into new revenue source through agreement with Manuka Pharma Thu, 18 Jan 2018 10:53:00 +1100 The Hydroponics Company positions itself to take advantage of Australian market Tue, 16 Jan 2018 12:27:00 +1100 Paradigm Biopharmaceuticals granted European patent Tue, 16 Jan 2018 10:04:00 +1100 The Hydroponics Company appoints finance specialist as director Mon, 15 Jan 2018 10:14:00 +1100 Creso Pharma to generate new revenue stream through cannabis beverage market Thu, 11 Jan 2018 14:45:00 +1100 Pharmaxis strengthens balance sheet with $15 million milestone payment Thu, 11 Jan 2018 11:55:00 +1100 ResApp Health set to begin U.S. study of its app to diagnose respiratory diseases Thu, 11 Jan 2018 11:31:00 +1100 eSense-Lab expands partnerships Thu, 11 Jan 2018 10:36:00 +1100 Patrys' shares halted Thu, 11 Jan 2018 10:29:00 +1100 Cellmid achieves record quarterly sales for its hair care products Wed, 10 Jan 2018 15:01:00 +1100 Cellmid ends the year on a high note after achieving quarterly targets Tue, 09 Jan 2018 15:24:00 +1100 The Hydroponics Company raising $3 million for medicinal cannabis Mon, 08 Jan 2018 14:50:00 +1100 Resapp Health embarking on new study to evaluate efficacy Mon, 08 Jan 2018 13:38:00 +1100 AuMake International calls for trading pause pending business update Mon, 08 Jan 2018 10:17:00 +1100 Viralytics attracts funding support from Chinese life sciences company Mon, 08 Jan 2018 08:44:00 +1100 Elixinol Global eyes new cannabis opportunities after raising $20 million Fri, 05 Jan 2018 16:32:00 +1100 MMJ PhytoTech eyes new opportunities in the Australian medicinal cannabis sector Fri, 05 Jan 2018 12:41:00 +1100 The Hydroponics Company gets a lift following medicinal cannabis export approval Fri, 05 Jan 2018 11:37:00 +1100 Bod Australia secures supply deal for medicinal cannabis extracts Fri, 05 Jan 2018 09:10:00 +1100 MGC Pharmaceuticals launches cannabidiol cream for psoriasis Thu, 04 Jan 2018 12:34:00 +1100 Cann Group to get a boost from Australia’s new medical cannabis export policy Thu, 04 Jan 2018 11:18:00 +1100 Viralytics targets cash injection for cancer research Thu, 04 Jan 2018 10:35:00 +1100 Opthea starts clinical trial for diabetic blindness treatment Wed, 03 Jan 2018 10:48:00 +1100 Pharmaxis secures further Australian government reimbursement for Bronchitol Wed, 03 Jan 2018 09:07:00 +1100 The Hydroponics Company attracts investment from international fund Thu, 28 Dec 2017 10:39:00 +1100 The Hydroponics Company to sell unique lighting products for the cannabis market Thu, 21 Dec 2017 16:41:00 +1100 Anteo Diagnostics surges on lithium-ion leverage Tue, 19 Dec 2017 12:33:00 +1100 Cellmid receives funding from US strategic investor Mon, 18 Dec 2017 08:55:00 +1100 AtCor Medical signs $1 million contract with international pharmaceutical company Fri, 15 Dec 2017 13:00:00 +1100 Zelda Therapeutics' Dr Stewart Washer presents at Proactive's CEO Sessions Zelda Therapeutics' Dr Stewart Washer presents at Proactive's CEO Sessions

Wed, 15 Nov 2017 08:30:00 +1100
Skin Elements at the forefront of natural, organic skin care products Skin Elements focuses on natural and organic skin care products as an alternative to current chemical-based products.

Peter Malone, chairman of Skin Elements Ltd (ASX:SKN) discusses their recent joint venture agreement with Ageless Products Pty Ltd to distribute the Skin Elements’ product range into China and other major global markets.

Malone adds they see the UK market as a significant part of their plan and already have early sales into the European sector which they've been building on over the last six months.

Fri, 10 Nov 2017 19:44:00 +1100
Zelda Therapeutics closing in on development of autism clinical trial Dr Stewart Washer, executive director of Zelda Therapeutics Ltd (ASX:ZLD), discusses with Proactive the successful results from their recent observation autism trial in Chile.

The results showed that in a group of 21 patients cannabis extracts were significantly more effective than conventional medicines used, including atypical antipsychotics, and these extracts were well tolerated by the patients overall.

Mon, 30 Oct 2017 20:41:00 +1100
Pharmaxis' CEO Gary Phillips updates on partnership with Boehringer Ingelheim Pharmaxis will receive €10 million milestone payment when the first patient is dosed in this 2nd indication Phase IIa study.

Fri, 08 Sep 2017 08:25:00 +1000
Pharmaxis is set to commence phase 1 trials Gary Phillips, chief executive officer for Pharmaxis, speaks with Proactive Investors.

Thu, 07 Sep 2017 16:55:00 +1000
Cellmid's Maria Halasz talks outstanding study results and growing expansion plans Maria Halasz, chief executive for Cellmid, speaks with Proactive Investors.

Tue, 29 Aug 2017 07:21:00 +1000
Pharmaxis gets A$27M injection from Boehringer Ingelheim Gary Phillips, chief executive officer for Pharmaxis, speaks with Proactive Investors.

Mon, 28 Aug 2017 08:19:00 +1000
Regeneus achieves major milestones and secures critical Japan collaboration John Martin, chief executive for Regeneus, speaks with Proactive Investors.

Wed, 23 Aug 2017 18:54:00 +1000
Paradigm's drug developments sees growing market opportunities Paul Rennie, chief executive for Paradigm Biopharmaceuticals, speaks with Proactive Investors.

Fri, 18 Aug 2017 08:30:00 +1000
Dimerix Ltd's Kathy Harrison discusses positive outcomes from Phase II clinical trial Kathy Harrison, chief executive for Dimerix, speaks with Proactive Investors.

Wed, 19 Jul 2017 07:00:00 +1000
Admedus' Wayne Paterson discusses revenue strategy and pathway for CardioCel 3D Wayne Paterson, chief executive officer for Admedus, speaks with Proactive Investors.

Mon, 19 Jun 2017 08:00:00 +1000
Dimerix's Kathy Harrison discusses pending Phase 2 clinical trials Kathy Harrison, chief executive officer for Dimerix, speaks with Proactive Investors.

Wed, 14 Jun 2017 09:00:00 +1000
Pharmaxis Ltd's Gary Phillips reveals completed Phase 3 clinical trial of Bronchitol Gary Phillips, chief executive officer for Pharmaxis Ltd, speaks with Proactive Investors.

Tue, 13 Jun 2017 10:00:00 +1000
The Hydroponics Company showcases strategic plan at Proactive's CEO Sessions Dr Andrew Beehag, chief executive officer for Canndeo, speaks with investors at the Proactive's Spotlight CEO Sessions.

Fri, 19 May 2017 16:00:00 +1000
Zelda Therapeutics expands medical cannabis clinical trials Dr Stewart Washer, executive director for Zelda Therapeutics, speaks with Proactive Investors.

Tue, 09 May 2017 08:00:00 +1000
ReNeuron CFO 'very encouraged' with stroke study results ReNeuron Group Plc (LON:RENE) has delivered encouraging results from its phase II clinical study treating stroke patients with its CTX stem cell candidate.

CFO Michael Hunt tells Proactive: ''We're very encouraged by these results. The objective of the study  was to see if we could garner a strong enough clinical signal in disabled stroke patients to warrant taking this drug into much larger, pivotal clinical development''.

''I'm pleased to say that the readouts we've had from the study so far have met that objective''.

Thu, 08 Dec 2016 02:52:00 +1100
'Another milestone for the Genedrive platform' says CEO David Budd Genedrive PLC (LON:GDR) has received European regulatory sign-off for its rapid genotyping device for patients with hepatitis-c.

Chief executive David Budd tells Proactive: ''It's something that we're certainly excited about and I think another milestone in the development of our Genedrive handheld platform''.

''Today anyone trying to do this type of analysis is probably going to a speciality reference laboratory or a hospital environment to get the test done - generally they're expensive and the turnaround time tends to be reasonably long. What we've demonstrated here is that we can use our Genedrive device to genotype patients and we can do that in a near patient or point-of-care setting in under an hour''.

Thu, 17 Nov 2016 23:51:00 +1100
Horizon Discovery's CareDx partnership validates model Horizon Discovery Group PLC (LON:HZD) says its continued collaboration with CareDx Inc validates its model.
Horizon makes cell lines, which can be used to stand in for real patient samples, and firms which are developing assays and research tools, can utilise them.
The latest agreement is to supply what it calls "cell-free DNA-based molecular reference standards" to CareDx as part of the latter’s research into transplanted organ rejection.
It's an important area as often patients own samples are not available or consistent enough for reliable usage, explains Chris Claxton, the firm's vice president for IR and corporate relations.
It provides an initial revenue stream to start with and the potential that groups like CareDX will continue to use them as a partner longer trem.
"We are looking to do many CareDxs, said Claxton. "We're looking to layer on many, many revenue streams, not just from a single organisation."
The firm is aiming to  be EBITDA (underlying earnings) positive in 2017.

Thu, 10 Nov 2016 02:27:00 +1100
New facility 'essential to Concepta PLC's growth' says CEO Erik Henau Concepta PLC (LON:CPT) has taken out  a ten year lease on a new manufacturing facility in Doncaster.
CEO Erik Henau tells Proactive: ''It'll be the UK manufacturing side for our diagnostic tests which fit our MyLotus meter - so initially we'll be making the pregnancy test and the ovulation test in the UK with processes that are completely controlled by ourselves.'' The factory will be ready in the first quarter of 2017, with all customer-facing staff also to be based there. In terms of capacity, Henau added ''we have huge expectations and the market is very large both in China, the UK  ... it's a global issue we're addressing''.

Tue, 08 Nov 2016 23:18:00 +1100
NetScientific plc chief hails progress at Vortex Biosciences NetScientific plc (LON:NSCI) chief executive and chairman Francois Martelet hailed recent news from portfolio company Vortex Biosciences as a "very important" milestone.
Vortex has been awarded a CE Mark for its circulating tumour cell (CTC) capture system and has registered a Class I medical device with the US FDA (Food and Drug Administration).
It means moving the selling of the VTX-1 Liquid Biopsy System closer in Europe and the USA - firstly for research use only.
Martelet said it was an exciting validation of the technology, which offers a high level of purity and collection efficiency against other methods of cell capture.
"Most patients don't die because of their tumours. Most patients die because of circulating tumour cells, which down the road, lead to metastasis," he highlighted.

Tue, 08 Nov 2016 01:15:00 +1100
Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the orphan drug space ... acromegaly is exactly that, it is classified as an orphan condition with an estimated prevalence of 60 patients per million of population''.
''Orphan status is the same in Europe and the USA - it's designed to encourage companies like ourselves to develop treatments for rare conditions. We get marketing exclusivity and also don't require the same number of patients for clinical trials'', Nealon added. Amryt has already been awarded orphan drug status for its lead drug EpiSalven, to treat the skin disorder Epidermolysis Bullosa, which is being prepared for a phase III trial early next year.

Tue, 08 Nov 2016 01:10:00 +1100
Biovault tie-up a 'landmark development' for WideCells Group PLC WideCells Group’s (LON:WDC) subsidiary CellPlan has signed a non-binding letter of intent to offer its stem cell treatment insurance to clients of the human tissue storage facility Biovault Technical. Biovault has a register of over 25,000 customers which WideCells will have access to for an initial five year term.

WideCells CEO chief executive João Andrade tells Proactive: ''This is a very important landmark for us because we have developed the product and now the market's responding positively to it. This letter of intent will allow us to have access directly to around 25,000 clients who Biovault currently has through their own company and also its affiliates and that will enable us to be able to rollout CellPlan during the course of next year''.

''What we'll be doing, until the end of this year, is developing together with Biovault, an implementation plan and a market roll out plan because Biovault is operating in several countries - not just in the UK'',  Andrade added.

Mon, 07 Nov 2016 22:17:00 +1100
Deltex Medical Group PLC poised for rapid US growth Deltex Medical Group plc (LON:DEMG) would not be the first British company to find a more welcome reception in the USA than in its home, and it has just announced that its US sales have overtaken those from the UK for the first time.
Chief executive officer Ewan Philips tells Proactive Investors that the company now has 27 “platform accounts” in the USA, which will form a bridgehead for its US sales initiatives. Sadly, back in Blighty, despite masses of evidence pointing to the superiority of its oesophageal Doppler monitoring technology (ODM) and a recommendation that it should be taken up by UK hospitals, inertia rules the day. Philips says the company has reverted to its old sales policy of “knocking on surgery doors” to persuade surgeons of the benefits of ODM.

Fri, 09 Sep 2016 00:08:00 +1000
Compumedics' Ltd Chairman and CEO David Burton talks to Proactive Investors TV ASX:CMP) is a revenue generating medical device company, with its share price doubling in the past year. Opportunity to continue its strong sales growth in China, and to expand into other global markets. ]]> Fri, 06 May 2016 12:01:00 +1000 Admedus Ltd's COO Julian Chick talks to Proactive Investors on interim Herpes Simplex Virus Phase II clinical trial data ASX:AHZ) is a leading diversified healthcare group. ]]> Tue, 08 Mar 2016 09:30:00 +1100 OncoSil Medical's MD Daniel Kenny spells out the pathway to CE Mark with Proactive Investors ASX:OSL) lead product candidate is the OncoSil™ medical device, which is focussed on localised radiation treatment for cancer. ]]> Sun, 04 Oct 2015 09:26:00 +1100 Uscom's CEO Rob Phillips talks revenue growth at Proactive's Luncheons ASX:UCM) is a revenue generating cardiovascular medical technology company that is carrying out due diligence to acquire Thor Laboratories KFT. ]]> Fri, 18 Sep 2015 09:00:00 +1000 Medibio's CEO Kris Knauer brings near-term revenues to Proactive's Luncheons Tue, 08 Sep 2015 15:00:00 +1000 OncoSil Medical CEO Daniel Kenny talks to Proactive Investors about the company's fight against cancer ASX:OSL) is developing safer and more effective ways to deliver radiation therapy to cancer patient’s tumours ]]> Thu, 21 May 2015 11:00:00 +1000 Imugene Limited CEO Charles Walker speaks about using Immuno-oncology in the fight against cancer ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies ]]> Wed, 10 Dec 2014 12:27:00 +1100